Ijzerhydroxide Sacharose Complex Teva

Iron sucrose, the active ingredient in Ijzerhydroxide Sacharose Complex Teva, is an iron preparation presented as an injectable solution for intravenous, intramuscular, and intra‑articular use. It treats iron deficiency anemia and anemia of chronic kidney disease in adult patients.

GNH USA supplies Ijzerhydroxide Sacharose Complex Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ijzerhydroxide Sacharose Complex (iron sucrose) is used to correct iron deficiency in conditions where oral iron is ineffective or not tolerated. - Iron deficiency anemia: restores hemoglobin and replenishes depleted iron stores. - Anemia of chronic kidney disease: supports erythropoiesis in patients receiving dialysis or renal replacement therapy. - Anemia in patients undergoing major surgery: improves pre‑operative iron status to reduce transfusion requirements.

Iron sucrose may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset after infusion. - Headache: transient headache during or after administration. - Injection site pain: local discomfort or erythema at the infusion site. - Muscle cramps: occasional leg or calf cramps. - Transient hypertension: temporary rise in blood pressure. - Flushing: brief sensation of warmth or redness.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Acute hypotension: sudden drop in blood pressure during infusion. - Iron overload: excessive iron accumulation with long‑term use. - Acute respiratory distress: rare severe breathing difficulty.

Before initiating therapy with iron sucrose, several safety considerations should be observed. - Assess iron status: confirm iron deficiency with laboratory tests before treatment. - Monitor hematologic response: regularly check hemoglobin, ferritin, and transferrin saturation. - Avoid in hypersensitivity: do not administer to patients with known allergy to iron sucrose. - Caution with infection: defer treatment in patients with active systemic infections. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Iron sucrose can interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Oral iron supplements: concurrent use may reduce absorption of each product. - Erythropoiesis‑stimulating agents: combined use can increase risk of hypertension. - Parenteral vitamin C: may increase free iron and oxidative stress.

Moderate Interactions (Monitor Closely): - Antihypertensive drugs: monitor blood pressure as iron sucrose may affect control. - Other IV iron formulations: concurrent use raises risk of iron overload. - Quinolone antibiotics: may chelate iron and reduce antibiotic effectiveness.